TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

Trial Title: TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

NCT ID: NCT06455917

Condition: Non-Small Cell Lung Cancer

Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

Conditions: Keywords:
tumor-infiltrating lymphocytes
adoptive cell therapy

Study type: Interventional

Study phase: Phase 2

Overall status: Not yet recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Combination of TIL Transfer and low dose IL-2
Description: The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment. - TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0). - Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses).
Arm group label: Tumor-infiltrating lymphocyte product (TIL) transfer

Summary: Aim of the study is to investigate the efficacy and safety of Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in NSCLC patients in a phase II clinical trial.

Detailed description: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a personalized immunotherapy. In patients with advanced Non-Small Cell Lung Cancer (NSCLC), a phase I clinical trial has investigated TIL-ACT in patients who progressed during ICI-treatment. For TIL-ACT, tumor-specific T cells are expanded from excised tumor samples and stimulated in cell culture with interleukin-2 (IL-2). The resulting autologous TILs are then re-infused to the patient after a non-myeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Activation of TILs in the patient is then supported by IL-2 administration.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Ability of the patient to understand the purpose of the study, provide signed and dated informed consent prior to performing any protocol-related procedures (including screening evaluations), and be able and willing to comply with the study procedures. 2. Age ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 (cf. Appendix). 4. Histologically confirmed NSCLC. 5. Disease progression after at least one standard therapy and without any approved curative-intended treatment option. 6. Accessible tumor lesion/metastasis for tumor collection. 7. Willingness of the patient to undergo a surgical intervention (eg, surgical resection and/or biopsy) to collect one or more tumor lesions/metastases. 8. Adequate organ function (pulmonary, cardiovascular, hematological, hepatic, and renal function) per investigator's judgment. Cardiac stress testing is required for all patients with underlying cardiac conditions and patients with age ≥ 50 years. 9. Negative serum pregnancy test in women of childbearing potential, in peri-menopausal women and in women with less than 2 years of menopause. Exclusion Criteria: 1. Active central nervous system (CNS) metastases. Patients with stable CNS metastases ≥ 1 month after definitive treatment (eg, surgery and/or radiotherapy) are eligible. 2. Participants with an active second malignancy. 3. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol, including autoimmune or immunodeficient conditions, significant pulmonary disease, significant cardiac and/or vascular disease per investigator's judgment. 4. Prior immune-related adverse events that would preclude re-challenge with an immune checkpoint inhibitor or immunomodulatory agent per investigator's judgment. 5. Immunosuppressive treatment that would preclude the patient from any of the study therapies per investigator's judgment. 6. Severe active infections or uncontrolled infectious conditions requiring treatment. 7. Any other conditions/diseases, allergies, dysfunctions, and/or findings, that would contraindicate the use of any of the study interventions or therapies. 8. Contraindication for any of the planned measures, interventions and/or treatments. 9. Pregnant or breastfeeding women, or female subject who are not willing to use an acceptable, highly effective method of contraception until the End-of-Study visit. 10. Known hypersensitivity to any of study therapies or drugs used for TIL production. 11. Known human immunodeficiency virus (HIV) infection (or tests positive for HIV 1 or 2 at Screening). 12. Known hepatitis B or hepatitis C infection.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: University Hospital Basel

Address:
City: Basel
Zip: 4031
Country: Switzerland

Contact:
Last name: David König, MD

Phone: +41 61 265 50 74
Email: david.koenig@usb.ch

Contact backup:
Last name: Heinz Läubli, Prof.

Phone: +41 61 265 50 74
Email: heinz.laeubli@usb.ch

Investigator:
Last name: David König, MD
Email: Principal Investigator

Investigator:
Last name: Heinz Läubli, Prof.
Email: Sub-Investigator

Investigator:
Last name: Benjamin Kasenda, PD MD
Email: Sub-Investigator

Start date: July 2024

Completion date: December 2029

Lead sponsor:
Agency: University Hospital, Basel, Switzerland
Agency class: Other

Source: University Hospital, Basel, Switzerland

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06455917